Protecting Axons Protecting Patients Creating breakthrough therapeutics for neurological diseases learn more cADPR and NF-L are SARM1-Dependent Biomarkers of Axonal Structure and Function that Enable Therapeutic Discovery and Clinical Translation March 11, 2019 publication + Disarm Therapeutics Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer July 22, 2019 press release + A New Approach to Treating Multiple Sclerosis News +
